A world-first, international study of a common treatment for women with Type 2 diabetes, has found that the drug may also offer a range of health benefits should they become pregnant.
Researchers from Western Sydney University participated in the ‘Metformin in women with Type 2 diabetes in pregnancy’ (MiTy) trial, led by Sinai Health in Canada – which tested the effects of the medication Metformin in pregnant women.
502 pregnant women with Type 2 diabetes from 29 centres in Canada and Australia participated in the study. The study was randomised, with the women taking either Metformin or a placebo, in addition to their usual insulin regimen.
The findings, which are published today in The Lancet Diabetes and Endocrinology, (opens in a new window) indicate that women who took Metformin during their pregnancy were more likely to experience a range of health benefits, including:
- better glucose control;
- lower insulin requirements;
- less gestational weight gain; and
- fewer caesarean births.
Read more (opens in a new window)